Time to end Rheumatic Heart Disease: Lessons and opportunities from observational registries by Engel, Mark et al.
42
Time to end Rheumatic Heart 
Disease: Lessons and opportunities 
from observational registries
COMMENTARY
objectives. Establishing a registry is a simple and effective way of 
establishing the burden of disease,(2) as well as, in the case of 
ARF/RHD, a method for monitoring the efficient delivery of 
prophylaxis and service delivery.(3) Furthermore, through docu-
menting treatment and outcomes in local practice, registries 
could serve to fill important knowledge gaps in the biology of a 
disease and its management strategies – both within and 
between regions.(4) Use of a comprehensive registry was touted 
as a key strategic target by the World Heart Federation in 
regions where RHD is endemic.(5)
Criteria have been suggested to evaluate the effectiveness and 
contribution of registries to the evidence base.(2) The stated 
purpose and objectives of establishing a registry must be clear, 
so as to guide its structure and setting. For example, it is 
important to clarify early on whether the registry will be facility-
based or community-based. Clearly defining the function of 
the registry will also serve to guide the scope, duration, and 
expected outcomes. Case definitions must be according to 
acceptable standards, with consideration given to mandating 
the use of specialised equipment or techniques in resource-
challenged environments. Next, it must be borne in mind that 
the potential for under-reporting may severely compromise 
the quality of collected information.(6) Thus, it may be worth-
while incorporating into the data collection, existing alternative 
sources such as laboratory reports or discharge information – 
so as to reduce reliance on the human interface. 
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INTRODUCTION
Rheumatic Heart Disease (RHD), the permanent sequel of 
Group-A streptococcal disease and the autoimmune phenom-
enon Acute Rheumatic Fever (ARF), disproportionately affects 
young people living in low- and middle-income countries. It 
impacts on fragile health systems, as well as regions of poor 
health access within more developed countries. The most 
recent Global Burden of Disease estimates that in 2015 there 
were 33.4 million RHD cases globally.(1) For a disease that is 
entirely preventable, this is unacceptable. A concerted global 
effort is gaining momentum to prevent, manage and eventually 
eradicate RHD at multiple intersects. In this paper, we focus 
on key lessons and opportunities, and highlight the role that 
observational studies will play in achieving control, and the 
ultimate elimination of RHD.
Registries and the evidence base
A registry may be defined as a database of identifiable persons 
containing a clearly defined set of health and demographic data 
collected for a specific public health purpose. It is not merely a 
paper or electronic database, but is developed to address spe-
cific health-related questions and to meet predetermined 
The fi ght against Rheumatic Heart Disease (RHD) is at 
a critical juncture. Despite the adoption of a global 
resolution by the World Health Assembly against RHD 
in May 2018, practitioners working in countries where 
RHD is endemic continue to be faced with an over-
whelming clinical burden, lack of surgical and inter-
ventional resources, and insuffi cient opportunities and 
funding for research. Recent years have seen the publi-
cation of several observational registries, most of which 
were investigator-initiated, not supported by larger 
research funders, and coordinated by small teams using 
paper-based infrastructure. This commentary refl ects 
on the lessons and opportunities that these registries 
have afforded the fi eld and suggests some areas for 













It must be emphasised that good methods are critical. We 
suggest that careful attention be given to the preparation of a 
manual of operations, which includes definitions, derivations, 
analyses, plans and the key hypothesis or hypotheses under-
pinning the existence of the registry. A peer-reviewed rationale 
and design publication should preferably precede commence-
ment of the implementation of a registry.(5,12) Box 1 outlines 
key components of a robust registry.
Any discussion on the implementation of registries cannot 
ignore consideration of the benefits of using digital technology. 
Even in resource-challenged environments, extensive network 
coverage and mobile use is extremely high.(7) The digital plat-
form can serve as the optimal platform to overcome the high 
cost of maintaining a paper-based registry, and the human 
resources of managing the day-to-day aspects of a registry. 
Before implementation, practical feasibility of the registry, 
especially in terms of likelihood of suff icient “buy-in” by the 
anticipated consumers, is essential. A situational analysis of 
issues relating to cultural diversity and the attitudes and work-
load of healthcare workers may serve to identify potential 
structural and social barriers to implementation.(7) While the 
solution of using modern digital era technology to create 
patient-based registries goes some way to overcoming the 
problem of underutilisation of registry-based practice, it also 
introduces problems of its own, related specifically to the 
quality of data entered. Quality control and quality assurance 
should be strongly maintained in any database or registry 
creation. Adding a human interface in the form of dedicated 
personnel who control and review input and manage databases 
often differentiates good from poor databases. Good databases 
are easier to fund and to sustain over time.
Clinical registries also inform Global Burden of Disease data,(1) 
especially regarding morbidity, non-fatal sequelae and also help 
in the identification of further data needs. This is a key value of 
a registry, as it provides an understanding of issues beyond the 
mere prevalence of the RHD disease burden. Registry data 
have thus been paramount in defining Disability Adjusted Life 
Years (DALYs) and Quality Adjusted Life Years (QUALYs). 
We suggest that future Global burden of disease data needs, 
expressed in the recent publication,(1) such as stroke burden, 
surgical outcomes, and age at presentation, be included in 
future RHD registries. 
Signif icant challenges are inherent in a robust, sustainable 
registry, and the largest multi-site RHD registry recently 
published these in detail. A suggestion would be to consider 
process evaluation and qualitative assessment, alongside a 
register, to provide information regarding why certain elements 
worked or did not work and to understand more clearly why 
outcomes were achieved or not  (see Box 2). 
Local, global and regional scientifi c registries in 
RHD early documentation 
In the first part of the previous century, Bland and Duckett 
Jones published one of the most important longitudinal data-
sets on RHD, outlining the presenting clinical features, signs of 
BOX 1: RHD registries: key components to setting up a 
registry.
Articulate the purpose of the registry and outline the hypotheses under-
pinning it.
Determine if the registry is the best means to achieve this purpose (if only 
partially, it may require additional studies or processes alongside the 
registry).
Identify key stakeholders and determine the extent of the proposed 
register.
Assess the feasibility – the authors suggest a pilot study – with an evalua-
tion phase.
Build a team that is well versed in registry processes, including ethics 
approval, standard operating procedures and data integrity.
Establish a governance and oversight plan, including quality control and 
assurance.
Defi ne the scope of the registry, data needed (data, defi nitions and 
derivations document), outcomes measured, and target population. This 
may be defi ned by funding, although this should not restrict a registry that 
is not funded. This can be performed in stages according to funding.
Write a study protocol, including a detailed statistical analysis plan.
Develop an overall project plan, which can include stages, modules and 
up-scaling with funding.
Finally – apply for funding!
BOX 2: RHD registries: lessons learned.(33)
A register will not achieve desired outcomes if these are not articulated at 
the outset with a clear and direct hypothesis.
Involve all stakeholders as early as possible; capacity building is a key 
outcome of a multi-site register.
Identify research needs in stakeholders as early as possible and address 
these upfront – e.g. Good Clinical Practice (GCP) experience.
Research excellence, integrity and thorough attention to detail are key.
Registries have positive and negative effects on clinical practice, so be 
prepared for this and document these.
Funding is very important, but great registries can start without funding. 
Budget for monitoring, site visits and data checks.
On-site initiation and regular site visits and monitoring are extremely 
helpful and ensure data integrity.
Include patients as an important stakeholder group and consider the 
dissemination of the fi ndings of the register in the lay and scientifi c 
community.
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between disease states, and to evaluate the cost-effectiveness 
of potential interventions.(19) Of 591 patients evaluated for pro-
gression of disease, surgery or death, 96 (16.2%) patients had 
severe RHD at diagnosis. Of these patients, 50% had pro-
ceeded to valve surgery by 2 years, and 10% were dead within 
6 years. Of concern, however, was that although patients with 
mild RHD at diagnosis were the most stable, with 64% 
remaining mild after 10 years, 11.4% progressed to severe RHD 
and half of these required surgery.
Cost-effectiveness analyses
Registry data have also been used for cost-effectiveness analysis. 
One has investigated the cost of primary and secondary 
prophylaxis using registry data from Cuba,(20) and suggested 
from their preliminary findings that primary preventions could 
be the most efficient and cheapest approach in poor countries. 
Cannon, et al. used the multi-state models described previously 
to review a cost-effectiveness model of echocardiographic 
screening, with a suggested ICER of less than AUD50 000(21) 
per DALY averted, assuming that RHD can be detected >/=2 
years earlier by screening.
Policy and partnerships
Informed by these data providing compelling evidence of col-
lective neglect and a wide gap in any systematic effort to 
prevent control or manage RHD, key role-players and stake-
holders are finally joining forces to take action through policy 
initiatives and concrete plans.(22) These build on important 
previous initiatives, such as the Pan-African Society of Cardi-
ology-driven ASAP (Awareness, Surveillance, Advocacy and 
Prevention) programme(23-25) led by a global initiative of con-
cerned parties such as the World Heart Federation,(26) and 
spurred on by successful multi-pronged interventions incor-
porating registers that achieved successes in countries such as 
Cuba(27) and Tunisia,(28,29) Multiple forces have been united in 
the fight to eradicate the disease under the umbrella name 
“RHD Action”, resulting in an encouraging momentum of 
activity, and culminating in the promise of a global commitment 
on RHD.(30)
In 2015, a practical roadmap outlining 7 major barriers to RHD 
control in Africa, and strategies to address them, was developed. 
The plan, called the Addis Ababa Communique, encouraged 
partnerships between the African Union Commission of health 
ministries, academia, and other role-players – and provided a 
comprehensive actionable programme with measurable and 
achievable outcomes over pre-specified timeframes.(31)
Adding weight to this effort, in 2018 the executive board of 
WHO recommended a resolution on Rheumatic Fever and 
RHD, which was spearheaded by New Zealand, and for 
adoption at the 2018 World Health Assembly. The resolution 
compels governments and health bodies to recognise RHD as 
deterioration, and the mortality related to RHD in thousands of 
patients from Baltimore.(8,9) This dataset represented the first 
major study on RHD and resulted in the first version of the 
Jones criteria. The marked decrease in morbidity and mortality 
due to ARF and RHD in the United States, and discussed by 
Massel, et al., told the important story of primary prevention.(10) 
Despite the fact that these registries are now almost a century 
ago, they still speak to the need for registries to demonstrate 
the start and end of this epidemic.
Recent registries: single-centre, country or multi-
country
Almost 80 years after the publication of the first longitudinal 
dataset, Sliwa, et al. published a study of newly diagnosed RHD 
in the Heart of Soweto study, which demonstrated an alarming 
incidence of 24.7 per 100 000 and the need for surgery for 
>20% of patients diagnosed with RHD within 20 months.(11) 
This was followed by the multi-country prospective Global 
Rheumatic Heart Disease registry,(12) REMEDY, which confirmed 
that of 3 343 patients from Africa , Yemen and India, the vast 
majority were women, young, severely affected, and with signi-
ficant gaps in evidence-based interventions and a desperate 
need for cardiac surgery and catheter interventions.(13) These 
results echoed the findings of a Turkish study, published in 
2013, which reviewed the etiologies of valve disease in 1 300 
patients across Turkey,(14) with RHD being the major cause of 
valvular heart disease. Two other countries that have significant 
burden of RHD have reported data, which have informed the 
field: India and Uganda. In India, a 3-year prospective paediatric 
registry showed good adherence to penicillin prophylaxis. 
Females had greater disease severity and 20% of patients 
underwent a guideline-recommended intervention. In the 
Uganda Heart Institute (UHI), 80% of patients are symptomatic 
on first diagnosis, with 40% already having significant cardio-
vascular complications.(15) A further registry from sub-Saharan 
Africa, The VALVAFRIC study, reviewed RHD in Western and 
Central Africa with a retrospective and prospective design, and 
reported that patients with RHD hospitalised in sub-Saharan 
Africa are young, socially disadvantaged, with a high mortality 
rate, and with extremely low access to surgery.(16)
Long-term outcomes
Okello, et al. reported on the 12-month outcomes of patients 
enrolled in the UHI registry; there were 59 deaths with a 1-year 
mortality rate of 17.8%. Most deaths occurred within the first 3 
months of presentation.(17) After 24 months, REMEDY reported 
an overall mortality of 16.9% with a median age of death of 28 
years, and with the highest rates in low-income countries – 
despite age and sex adjustment.(18) Both the Indian paediatric 
RHD registry and the VALVAFRIC study reported high mortality 
rates of 3.1% and 16% respectively. In an elegant publication 
from Australia, Cannon, et al. used Northern Territory data to 
develop multi-state models to estimate rates of transition 













a global health priority and to commit appropriate resources 
and funds toward prevention and control.(32) It represents a 
seismic shift in the RHD landscape. We stand at the precipice 
of RHD activism; now is the time to act decisively and to 
diagnose Strep A as early as possible, to institute treatment to 
prevent ARF, and to manage RHD effectively. The WHO 
resolution is summarised in Table 1, and the mandate of incor-
porating patients at the centre of all activities speaks strongly 
to a patient-based infrastructure – which is the key component 
of an effective registry. New registers being developed for 
RHD need to consider key questions in RHD prevention, con-
trol and surveillance, in order to meet the high expectations of 
the resolution (see Box 3).
In summary
Retrospective, and more recently large-scale multi-country 
prospective registries in RHD, provide a unique opportunity to 
accurately assess current clinical practice and outcomes. They 
allow for comparison of data with other institutions and clinical 
practice guidelines. In particular, they inform the Global burden 
of disease data,(1) especially regarding morbidity and non-fatal 
sequelae and help identify further data needs. In RHD, registries 
have made a critical contribution to our evidence base, clinical 
management and advocacy efforts. However, they are only 
useful when used properly, and with careful attention to design, 
analysis and interpretation.
TABLE I: World Health Assembly Resolution against Rheumatic Heart Disease. 
The resolution urges member states to: The resolution invites relevant international stakeholders to assist and collaborate and: 
Accelerate multisectoral efforts toward reducing poverty, 
improving socioeconomic conditions and tackling the known 
root determinants of rheumatic heart disease.
Put people living with rheumatic heart disease at the centre 
of the prevention and control agenda, and advocate on 
behalf of communities affected by rheumatic heart disease.
Estimate their burden of rheumatic heart disease, implement 
and resource rheumatic heart disease programmes, and 
provide improved disease surveillance and good-quality data 
analysis that facilitate appropriate follow-up and contribute 
to a broader understanding of the global disease burden.
Raise the profi le of rheumatic heart disease and other 
non-communicable diseases of children and adolescents on 
the global agenda – with a view to strengthening health 
systems and alleviating poverty.
Improve access to primary healthcare, and a primary 
healthcare workforce trained in prevention, diagnosis and 
evidence-based management, alongside improving 
understanding of prevention and control of rheumatic heart 
disease among at  risk populations.
Facilitate timely, affordable and reliable access to existing and 
new cost-effective medicines and technologies for the 
prevention and control of rheumatic heart disease and for 
supporting research and development.
Ensure timely, affordable and reliable access to cost-effective 
essential laboratory technologies and medicines, for the 
diagnosis, prevention and treatment of acute rheumatic fever 
and rheumatic heart disease.
Strengthen national and international cooperation to address 
rheumatic heart disease, including through setting global and 
national targets, using and sharing best practice 
methodologies for prevention and control, and creating 
national and regional networks.
The WHO Director-General 
is requested to:
Reinvigorate engagement, lead and coordinate global efforts on prevention and control of rheumatic disease – with rheumatic 
heart disease considered broadly across relevant WHO work areas.
Support member states in identifying the rheumatic heart disease burden and, where appropriate, developing and 
implementing rheumatic heart disease programmes and strengthening health systems.
Foster international partnerships for resource mobilisation, sharing best practice etiologies, developing and supporting a 
strategic research and development agenda, and facilitating access to existing and new medicines and technologies.
Assess and report on the magnitude and nature of the problem of rheumatic heart disease according to agreed measures, and 
monitor efforts for the prevention and control of rheumatic heart disease.
Report on implementation of this resolution to the 74th World Health Assembly.
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BOX 3: RHD registries: future needs.
Monitor the global burden of disease and regional prevalence and 
incidence trends.
Provide better understanding of the immunopathogenesis and biology of 
RHD.
Monitor adherence to guidelines recommended for prevention and pro-
phylaxis and understand regional variations.
Monitor adherence to guideline recommended treatment strategies and 
understand region variations.
Provide data to improve understanding of regional variation.
Provide data to inform future trials of therapeutic interventions.
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